Ziegels P, Nocaudie M, Huglo D, Deveaux M, Detourmignies L, Wattel E, Marchandise X
Service Associé de Médecine Nucléaire, Hôpital Cl. Huriez, Chu de Lille, France.
Eur J Nucl Med. 1995 Feb;22(2):126-31. doi: 10.1007/BF00838942.
The aim of this study was to compare the value of scintigraphy using technetium-99m methoxyisobutylisonitrile (MIBI) with that of scintigraphy using gallium-67 citrate in the assessment of Hodgkin's disease and non-Hodgkin's lymphoma and to relate these results with those of CT scan and MRI. Fifty-eight patients were included either for a follow-up examination or for monitoring of their treatment. Twenty-three residual masses were studied. A whole-body scan was performed, followed by single-photon emission computed tomography (SPET) 20 min after injection of 740 MBq of 99mTc-MIBI and 72 h after injection of 185 MBq of 67Ga citrate. The overall sensitivity of 99mTc-MIBI and 67Ga citrate was 71% and 68%, respectively, and the overall specificity was 76% and 44%, respectively. For residual masses, the sensitivity was 44% with both tracers and the specificity was 80% with 99mTc-MIBI and 53% with 67Ga citrate. The positive predictive values were 85% and 68% and the negative predictive values were 59% and 44%, respectively. The signal-to-background ratio was 1.5 for 99mTc-MIBI and 2 for 67Ga citrate. At present, 99mTc-MIBI cannot replace 67Ga citrate in the assessment of lymphomas.
本研究的目的是比较使用99m锝-甲氧基异丁基异腈（MIBI）的闪烁扫描法与使用枸橼酸镓-67的闪烁扫描法在评估霍奇金病和非霍奇金淋巴瘤中的价值，并将这些结果与CT扫描和MRI的结果相关联。纳入了58例患者进行随访检查或治疗监测。对23个残留肿块进行了研究。进行了全身扫描，然后在注射740 MBq的99mTc-MIBI后20分钟以及注射185 MBq的枸橼酸镓-67后72小时进行单光子发射计算机断层扫描（SPET）。99mTc-MIBI和枸橼酸镓-67的总体敏感性分别为71%和68%，总体特异性分别为76%和44%。对于残留肿块，两种示踪剂的敏感性均为44%，99mTc-MIBI的特异性为80%，枸橼酸镓-67的特异性为53%。阳性预测值分别为85%和68%，阴性预测值分别为59%和44%。99mTc-MIBI的信号与本底比为1.5，枸橼酸镓-67的信号与本底比为2。目前，在淋巴瘤评估中99mTc-MIBI不能替代枸橼酸镓-67。
